Coacervate micro and/or nano droplets and hydrogels

Patent metadata

Field	Value
Publication number	US-10729776-B2
Application number	US-201816155436-A
Country	US
Kind code	B2
Filing date	Oct 9, 2018
Priority date	Jul 9, 2014
Publication date	Aug 4, 2020
Grant date	Aug 4, 2020

Abstract

A composition includes a plurality of coacervate micro and/or nanodroplets of oxidized alginate and a methacrylated gelatin.

First claim

Having described the invention, we claim:

1. A method for promoting tissue growth in a subject comprising:
administering a coacervate hydrogel to a target site in the subject, the coacervate hydrogel comprising: crosslinked oxidized alginate and methacrylated gelatin that form a hydrogel matrix and a plurality of coacervate microdroplets and/or nanodroplets suspended in the matrix, wherein the oxidized alginate has an oxidation percentage of at least 10% of uronic acid units of alginate and the methacrylated gelatin has a methacrylation percentage of about 10% to about 99% of amine groups of gelatin.

2. The method of claim 1 , wherein at least one bioactive agent is incorporated in the coacervate microdroplets and/or nanodroplets and/or matrix.

3. The method of claim 1 , wherein the oxidized alginate has an oxidation percentage of up to 50% of uronic acid units of alginate.

4. The method of claim 1 , wherein the oxidized alginate is methacrylated and has a methacrylation percentage up to 45% of alginate carboxylic acid reactive groups.

5. The method of claim 2 , wherein the hydrogel matrix includes a plurality of cells and the plurality of coacervate microdroplets and/or nanodroplets provide controlled release of the bioactive agent to the plurality of cells.

6. The method of claim 5 , wherein the bioactive agent comprises BMP-2 and the cells comprise hMSCs.

7. The method of claim 1 , wherein the coacervate hydrogel is administered to a tissue defect.

8. The method of claim 7 , wherein the tissue defect is a bone and/or cartilage defect.

9. A method for promoting tissue growth in a subject comprising:
administering a coacervate hydrogel to a target site in the subject, the coacervate hydrogel comprising: a crosslinked oxidized methacrylated alginate and a methacrylated gelatin that form a hydrogel matrix and a plurality of coacervate microdroplets and/or nanodroplets, wherein the oxidized methacrylated alginate has an oxidation percentage of 10% up to 50% of uronic acid units and a methacrylation percentage up to 45% of carboxylic acid reactive groups of alginate, the methacrylated gelatin has a methacrylation percentage of at least about 10% to about 99% of amine groups of alginate.

10. The method of claim 8 , wherein at least one bioactive agent is incorporated in the microdroplets and/or nanodroplets and/or matrix.

11. The method of claim 10 , wherein the hydrogel matrix includes a plurality of cells and the plurality of coacervate microdroplets and/or nanodroplets provide controlled release of the bioactive agent to the plurality of cells.

12. The method of claim 11 , wherein the bioactive agent comprises BMP-2 and the cells comprise hMSCs.

13. The method of claim 9 , wherein the coacervate hydrogel is administered to a tissue defect.

14. The method of claim 13 , wherein the tissue defect is a bone and/or cartilage defect.

Assignees

• Univ Case Western Reserve

Inventors

• Alsberg Eben
• Jeon Oju
• Wolfson David

Classifications

• A61K38/1875 Primary

  Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor · CPC title

• A61K35/28

  Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells · CPC title

• A61L27/54

  Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)} · CPC title

• A61L27/26

  Mixtures of macromolecular compounds · CPC title

• A61K31/727

  Heparin; Heparan · CPC title